Company profile
Summit Therapeutics Limited is a UK company with status active founded in 2004 based in South East England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0MjM4MDYwNmFkaXF6a2N4 | Paper/PDF filed
Published 09 Nov 2024 07:27
CS01 | Transaction MzQzODMzMjA3OWFkaXF6a2N4
Published 03 Oct 2024 07:34
Company registered at Companies House
1 Sep 2013 to 31 Aug 2016
Duchenne Muscular Dystrophy (‘DMD’) is a fatal genetic disease that affects approximately 1,500 boys and young men in the UK. There is currently no disease modifying treatment for this progressive muscle wasting disease. Summit, a UK drug discovery and development company, is developing SMTC1100, a utrophin modulator drug that has the potential to treat a...
1 Oct 2012 to 31 May 2013
Alzheimer's disease (AD) is the most common form of dementia with existing AD treatments only providing symptomatic relief. There remains a high need for the development of new, disease modifying medicines that affect the progression of the disease. A hallmark of AD is the formation in the brain of tangles resulting from aggregation of the protein tau tha...
1 Apr 2007 to 31 Mar 2010
To establish a hepatotoxicity biomarker database in zebrafish embryos (ZFEs) using compounds with known toxicities. To use this database in parallel with OGeS''s existing OGAP database to select and validate potential drug safety protein biomarkers in both ZFEs and rodents (and ultimately, man). To develop highthroughput Ordered Peptide Array (OPA) screen...
